Stage 4 cancer is when the cancer has spread beyond its original location to other parts of the body. While this stage is not curable, it can be treated with a combination of medications and radiation therapy to extend survival. Some patients with stage 4 cancer also choose to use the Joe Tippens Cancer Protocol. This involves using a combination of the anticancer drug fenbendazole and the natural compound berberine. This treatment reduces the ability of cancer cells to take up glucose, starving them of their primary source of energy.
Fenbendazole is a broad-spectrum benzimidazole anthelmintic agent with an excellent safety margin and wide antiparasitic activity in many animal species. It also inhibits microtubule polymerization and exerts antitumor effects in human cancer cells. Its potential for repurposing in humans, resulting in an improved tolerability profile with less toxicity, has been demonstrated in genitourinary malignancies.
The present study investigated the effect of fenbendazole on necroptosis in colorectal cancer (CRC) cells and patient-derived CRC organoids. In both SNU-C5 and SNU-C5/5-FUR cells, fenbendazole significantly increased the activation of phosphor-receptor-interacting protein kinase (pRIP), RIP3, and phosphor-mixed lineage kinase domain-like protein (pMLKL) and induced caspase-8 activation. However, it did not significantly change the expression of LC3-I, Atg7, or Beclin-1.
Self-administration of fenbendazole, or its metabolite oxifendazole, was reported by an 80-year-old woman with advanced nonsmall cell lung cancer (NSCLC). She started taking fenbendazole because she heard about it on social media and believed it would cure her disease. Nine months later, she developed severe liver dysfunction. We report this case to highlight the need for physicians to inquire about the sources of medical information that patients acquire on social media. fenbendazole stage 4 cancer